BioDiscovery and Exiqon Sign OEM Agreement to Provide Complete miRNA Analysis Solution

EL SEGUNDO, CA, AND COPENHAGEN, DK, 5 May 2010 - BioDiscovery, Inc., a leader
in integrated software solutions for microarray-based research, and Exiqon A/S,
a leader in microRNA analysis products and services, announced today an OEM
Agreement incorporating BioDiscovery's array analysis and visualization
software with Exiqon's arrays. The agreement allows Exiqon to package
BioDiscovery's array image analysis and data analysis and visualization
software with Exiqon's microRNA arrays for a complete solution offering. 

“The partnership between BioDiscovery and Exiqon provides a complete well
integrated solution for microRNA array studies, going from array experiment
with Exiqon's miRCURY LNA™ microRNA Arrays to final results with data analysis
and visualization from BioDiscovery software,” said Soheil Shams, President of
BioDiscovery. “Now, regardless of the scanning equipment the customer is using,
our ImaGene software will allow efficient and accurate quantification of the
signals and our Nexus Expression for ImaGene software will provide
pre-processing and statistical analysis to identify differentially expressed
microRNAs and perform clustering analysis.” 

“The integration of ImaGene 9 and Nexus Expression 2 with the miRCURY LNATM
microRNA Arrays from Exiqon results in the most optimized and simplified
workflow available today,” said Henrik M. Pfundheller, VP Sales & Marketing of
Exiqon. “We can now provide researchers with the best performing microRNA
arrays on the market together with all other needed reagents, kits and software
analysis tools enabling researchers to get from RNA extraction, labeling of
samples, array hybridization, and further on to data analysis and
bioinformatics in an easy, fast and accurate way. As we also offer solutions
for downstream validation of array results including our LNA™ Universal RT
microRNA PCR product, customers can get a complete package for their microRNA
research at Exiqon.” 

BioDiscovery's software is platform independent and available for Mac OS X,
Linux and Windows operating systems. ImaGene is recognized by industry experts
as the most complete solution for array image analysis with the highest quality
results and the easiest to use microarray analysis user interface. With single
click automation, integrated advanced quality control parameters, numerous
patented segmentation and contamination removal algorithms, and hundreds of
active customers worldwide, ImaGene remains the leader in microarray image
analysis. Nexus Expression for ImaGene is a complete analysis package allowing
up to 24 samples to be simultaneously analyzed and visualized to identify
differentially regulated probes, cluster samples and probes and identify common
biological themes through gene set enrichment. With an intuitive interface and
rich graphical and numerical outputs that are publication ready, Nexus
Expression for ImaGene is an ideal product for those performing gene or
microRNA expression analysis.¨ 

Exiqon's miRCURY LNA™ microRNA Array system is a complete system for global
microRNA expression profiling. Featuring validated and Tm-normalized LNA™-based
capture probes, the miRCURY LNA™ microRNA arrays offer microRNA expression
profiling with unmatched specificity and sensitivity. With the recent launch of
our 5th generation array Exiqon now offers the most updated content on the
market with the array containing probes targeting more than 2520 human, mouse
and rat  microRNAs as well as viral microRNAs and 385 new proprietary human
miRPlus™ sequences. Exiqon also offers products for downstream validation of
arrays results including the miRCURY LNA™ Universal RT microRNA PCR for
validation by qPCR and miRCURY LNA™ microRNA Detection probes for validation by
in-situ hybridization. 

Additional information:
Soheil Shams, President & CSO BioDiscovery, Inc.
+1 310-414-8100
sshams@biodiscovery.com

Henrik M. Pfundheller, VP Sales & Marketing, Exiqon A/S
+45 4565 0420
hmp@exiqon.com

See the full press release in the attached PDF or at
www.exiqon.com/investor/portal